

28th International Conference on
CANCER RESEARCH AND ANTICANCER THERAPIES
International Conference on &
ONCOGENESIS & ONCOLOGIC EMERGENCY MEDICINE
3rd International Conference on &
TUMOR & CANCER IMMUNOLOGY AND IMMUNOTHERAPY
September 17-18, 2018 | San Diego, USA



Andrei L Gartel

University of Illinois at Chicago, USA

FOX(M1) and cancer

FOX(M1) is an oncogenic transcription factor that is overexpressed in the majority of human cancers and is a potential target for anticancer drugs. We identified proteasome inhibitors as the first type of drugs that target FOX(M1) in cancer cells. Moreover, we found that HSP90 inhibitor PF-4942847 that does not act as proteasome inhibitor also suppresses FOX(M1). Chaperone HSP70 is induced after treatment with both proteasome/HSP90 inhibitors and after heat-shock stress and we identified this chaperone as a novel negative regulator of FOX(M1) after proteotoxic stress. We showed that FOX(M1) and HSP70 interact in cancer cells following proteotoxic stress and FOX(M1)/HSP70 interaction led to inhibition of FOX(M1). We have previously shown that FOX(M1) interacts with nucleophosmin (NPM) in cancer cells and NPM determines the cellular localization of FOX(M1). Mutations in NPM1 result in cytoplasmic re-localization of NPM (NPM1^{mut}) and favorable outcome for the patients. We found the evidence that improved outcomes in the subset of NPM1^{mut} AML may be partially explained by the cytoplasmic re-localization and consequent functional inactivation of FOX(M1). First, we confirmed the co-localization of FOX(M1) and NPM1^{mut} in the cytoplasm of AML patients bone marrow biopsies and determined a strong cytoplasmic expression of FOX(M1) only in NPM1^{mut} AML cells. We also showed an important role of FOX(M1) in chemo-resistance in leukemia cell lines with nuclear, but not cytoplasmic FOX(M1). These data imply that suppressing of FOX(M1) in AML could increase sensitivity to standard chemotherapy.

Biography

Andrei L Gartel, PhD, is an Associate Professor in the Department of Medicine at the University of Illinois at Chicago and is the academic editor of PLOS ONE. He is the author of 90 peer-review publications that include more than 25 reviews. He has more than 11,000 citations and his h-index is 41. His scientific interests include cancer, regulation of oncogenic transcription factors FOX(M1), protein-protein interactions; cell cycle and regulation of CDK inhibitor p21. Specifically, his lab is interested in the identification of new FOX(M1) inhibitors. He received his funding from NIH, DOD and private companies/foundations.

agartel@uic.edu

Notes: